Yttrium (90Y) tacatuzumab tetraxetan: Difference between revisions
Appearance
Content deleted Content added
Updating {{drugbox}} (no changed fields - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wikipedia |
Anypodetos (talk | contribs) Move information about tetraxetan to its own page |
||
Line 40: | Line 40: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
| chemical_formula = C<sub>6470</sub>H<sub>9971</sub>N<sub>1712</sub>O<sub>2007</sub>S<sub>42</sub><sup>90</sup>Y |
| chemical_formula = C<sub>6470</sub>H<sub>9971</sub>N<sub>1712</sub>O<sub>2007</sub>S<sub>42</sub><sup>90</sup>Y |
||
| molecular_weight = 145 [[kDa]] |
| molecular_weight = 145 [[kDa]] |
||
}} |
}} |
||
'''Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan''' (trade name '''AFP-Cide''') is a [[humanize]]d [[monoclonal antibody]] intended for the treatment of cancer.<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium_90_tacatuz.doc Statement On A Nonproprietary Name Adopted By The USAN Counil]</ref> The antibody itself, tacatuzumab, is conjugated with a [[chelator]] for [[yttrium-90]]<ref>[http://apps.who.int/medicinedocs/documents/s14179e/s14179e.pdf WHO Drug Information]</ref>, a [[radioisotope]] which destroys the tumour cells. |
'''Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan''' (trade name '''AFP-Cide''') is a [[humanize]]d [[monoclonal antibody]] intended for the treatment of cancer.<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium_90_tacatuz.doc Statement On A Nonproprietary Name Adopted By The USAN Counil]</ref> The antibody itself, tacatuzumab, is conjugated with [[tetraxetan]], a [[chelator]] for [[yttrium-90]]<ref>[http://apps.who.int/medicinedocs/documents/s14179e/s14179e.pdf WHO Drug Information]</ref>, a [[radioisotope]] which destroys the tumour cells. |
||
The chelator ("tetraxetan") is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. The antibody is attached to one of the four carboxyl groups as an [[amide]], and the other three are [[carboxylate anion]]s neutralizing the three positive charges of the yttrium ion. |
|||
==References== |
==References== |
Revision as of 14:31, 29 October 2011
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | α-fetoprotein |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
Chemical and physical data | |
Formula | C6470H9971N1712O2007S4290Y |
Molar mass | 145 kDa |
(verify) |
Yttrium (90Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90[2], a radioisotope which destroys the tumour cells.
References